Key clinical point: Intranasal ketorolac was not inferior to intravenous ketorolac in reducing pain intensity 60 min postmedication in children with migraine headaches of moderate-to-severe pain intensity.
Major finding: The difference in mean pain reduction at 60 min between intranasal and intravenous ketorolac groups was 0.2 (95% CI −0.9 to 1.3), with intranasal ketorolac being noninferior to intravenous ketorolac ( P < .001). No serious adverse events were reported.
Study details: Findings are from a phase 3 clinical trial including 59 children (age 8-17 years) with migraine headache of moderate-to-severe pain intensity requiring any intravenous analgesic. They were randomly assigned to receive either intranasal ketorolac (1 mg/kg) or intravenous ketorolac (0.5 mg/kg).
Disclosures: This study was funded by the Columbia University’s CTSA grant from NCATS/NIH and Migraine Research Foundation. The authors declared no conflict of interests.
Source: Tsze DS et al. Acad Emerg Med. 2021 (Nov 25). Doi: 10.1111/acem.14422.